Gavi-Harvard Study Shows Vaccines Will Save Tens Of Millions From Poverty 05/02/2018 William New Vaccination will help prevent some 24 million people from falling into poverty by 2030 in addition to saving millions of lives, shows a new study co-authored by Harvard University and Gavi, the Vaccine Alliance. Continue reading -> Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading -> Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading -> Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading -> Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading -> Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading -> Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading -> Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 Guest contributor On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 Guest contributor Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts
Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Posts navigation Older postsNewer posts